文献速递血液净化与透析

接受透析治疗的肾衰竭患者的癌症死亡率:1980-2013年澳大利亚和新西兰队列研究

Cancer Mortality in People Receiving Dialysis for Kidney Failure: An Australian and New Zealand Cohort Study, 1980-2013.
PubMed 文献 · Am J Kidney Dis · 2022-04-30

该回顾性队列研究基于澳大利亚和新西兰透析与移植登记数据(1980-2013年),纳入59,648名透析患者,共34,100例死亡,其中3,677例为癌症死亡。透析患者全部位癌症死亡风险为一般人群的2.4倍(SMR 2.4 [95% CI 2.33-2.49]),口腔和咽部癌及多发性骨髓瘤的SMR最高。女性、血液透析患者风险更高,且随时间推移部分癌症的超额死亡下降但未跟上一般人群改善。

要点

  • 透析患者全部位癌症死亡风险是一般人群的2.4倍(SMR 2.4 [95% CI 2.33-2.49])。
  • 口腔和咽部癌(SMR 24.3)及多发性骨髓瘤(SMR 22.5)超额风险最高。
  • 女性全部位癌症死亡SMR 2.7高于男性2.3(P<0.001),血液透析SMR 2.2高于腹膜透析1.3。

核心结论

  • 透析患者全部位及部位特异性癌症死亡率均高于一般人群。
  • 癌症死亡率因透析方式、年龄和性别而异。
  • 理解肾衰竭和其他合并症在癌症治疗中的作用对共享决策和改善结局很重要。

研究设计与样本

  • 回顾性队列研究,使用关联的健康行政数据和透析登记数据。
  • 纳入1980-2013年澳大利亚和新西兰透析与移植登记中的所有透析患者,共59,648人。
  • 暴露为透析,包括血液透析(HD)和腹膜透析(PD)。
  • 结局为死亡及根本死因,使用ICD-10-AM编码分类。
  • 采用间接标准化法,按死亡年龄、性别、年份和国家估算标准化死亡比(SMR)。

主要发现

  • 共观察269,598人年,发生34,100例死亡,其中3,677例为癌症死亡。
  • 透析患者全部位癌症死亡SMR为2.4(95% CI 2.33-2.49)。
  • 口腔和咽部癌SMR为24.3(95% CI 18.0-31.5),多发性骨髓瘤SMR为22.5(95% CI 20.3-23.9)。
  • 女性全部位癌症死亡SMR为2.7(95% CI 2.59-2.89),男性为2.3(95% CI 2.17-2.36),差异P<0.001。
  • 血液透析患者全部位癌症死亡SMR为2.2(95% CI 2.11-2.30),腹膜透析患者为1.3(95% CI 1.23-1.44)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 无法获得癌症诊断确认和人群发病率数据。
  • 无法排除既往已存在的癌症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Cancer is a significant cause of morbidity in the population with kidney failure; however, cancer mortality in people undergoing dialysis has not been well described. We sought to compare cancer mortality in people on dialysis for kidney failure with cancer mortality in the general population. STUDY DESIGN: A retrospective cohort study using linked health-administrative and dialysis registry data. SETTING & PARTICIPANTS: All people receiving dialysis represented in the Australian and New Zealand Dialysis and Transplantation Registry, 1980-2013. EXPOSURE: Dialysis; hemodialysis (HD) and peritoneal dialysis (PD). OUTCOME: Death and underlying cause of death ascertained using health administrative data and classified using International Classification of Diseases, Tenth Revision, Australian Modification (ICD-10-AM) codes. ANALYTICAL APPROACH: Indirect standardization on age at death, sex, year, and country to estimate standardized mortality ratios (SMR). RESULTS: Over 269,598 person years of observation, 34,100 deaths occurred among 59,648 people on dialysis, including 3,677 cancer deaths. The relative risk of all-site cancer death in dialysis was twice (SMR, 2.4 [95% CI, 2.33-2.49]) that of the general population and highest for oral and pharynx cancers (SMR, 24.3 [95% CI, 18.0-31.5]) and multiple myeloma (SMR, 22.5 [95% CI, 20.3-23.9]). Women on dialysis had a significantly higher risk of all-site cancer mortality (SMR, 2.7 [95% CI, 2.59-2.89]) compared with men (SMR, 2.3 [95% CI, 2.17-2.36]) (P < 0.001). People on HD (SMR, 2.2 [95% CI, 2.11-2.30]) experienced greater excess deaths from all-site cancer compared with people on PD (SMR, 1.3 [95% CI, 1.23-1.44]). Excess deaths have gradually decreased over time for all-site, multiple myeloma, and kidney cancers (P < 0.001) but have not kept up with improvements in the general population. By contrast, among people receiving dialysis, excess deaths increased for colorectal and lung cancers (P < 0.001). LIMITATIONS: Confirmation of cancer diagnoses and population incidence data were not available; inability to exclude pre-existing cancers. CONCLUSIONS: People on dialysis experience excess all-site and site-specific cancer mortality compared with the general population. Mortality differs by modality type, age, and sex. Understanding the role of kidney failure and other morbidities in the treatment of cancer is important for shared decision-making regarding cancer treatments and identifying potential approaches to improve outcomes.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Rosales BM, De La Mata N, Vajdic CM, et al. Cancer Mortality in People Receiving Dialysis for Kidney Failure: An Australian and New Zealand Cohort Study, 1980-2013. Am J Kidney Dis. 2022. PMID: 35500725. doi:10.1053/j.ajkd.2022.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。